Ramucirumab 500mg Injection

Ramucirumab 500mg Injection is a highly specialized, fully human monoclonal antibody (IgG1) designed to disrupt the blood supply to tumors, a strategy known as angiogenesis inhibition. Tumors cannot grow beyond a certain size without developing their own network of blood vessels to deliver oxygen and nutrients. Ramucirumab 500mg Injection specifically targets the Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). By binding to this receptor with high affinity, the medication physically blocks the natural ligands (VEGF-A, VEGF-C, and VEGF-D) from attaching. This blockade prevents the activation of the signaling pathways that trigger endothelial cell proliferation and new blood vessel formation. Essentially, it starves the cancer cells by cutting off their lifeline, leading to tumor regression and inhibiting metastatic spread. Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for managing advanced gastric, lung, and colorectal cancers, offering a targeted biological option that works synergistically with standard chemotherapies.

The 500mg/50ml vial is the high-volume dosing unit designed to facilitate the preparation of adult dosages for patients with average to high body weight. Since dosing is weight-based (typically 8 mg/kg or 10 mg/kg), a single 500mg vial often forms the core of the infusion preparation, significantly reducing the number of individual vials needed compared to the 100mg size. This efficiency streamlines pharmacy workflow and reduces the risk of contamination during compounding. The medication is administered via intravenous infusion every 2 or 3 weeks,

Indications / Uses of Ramucirumab 500mg Injection

Ramucirumab 500mg Injection is commonly prescribed for the specialized management of the following advanced malignancies:

• Gastric/GEJ Cancer: It is indicated as a single agent or in combination with paclitaxel for the treatment of patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma who have progressed on prior fluoropyrimidine- or platinum-containing chemotherapy.
• Non-Small Cell Lung Cancer (NSCLC): The medication is used in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy.
• Colorectal Cancer: It is indicated in combination with FOLFIRI (irinotecan, folinic acid,
  

  Key Features

  • Specific VEGFR2 Blockade: The primary feature of Ramucirumab 500mg Injection is its direct inhibition of the primary receptor responsible for tumor angiogenesis, distinguishing it from drugs that target the ligand (VEGF).
  • High-Volume Efficiency: The 500mg vial size is optimized for standard adult weight-based dosing, minimizing the number of vials required per compounding session.
  • Synergistic Efficacy: Clinical trials demonstrate that it significantly improves overall survival when added to chemotherapy backbones like paclitaxel or docetaxel.
  • Starvation Mechanism: By preventing the formation of new blood vessels, it effectively limits the tumor’s supply of oxygen and nutrients.
  • Fully Human Antibody: As a fully human IgG1 antibody, it has a lower risk of inducing immunogenic reactions compared to chimeric antibodies.
    

    Storage for Ramucirumab 500mg Injection

    To preserve the structural integrity and biological activity of the monoclonal antibody, Ramucirumab 500mg Injection must be stored under refrigeration, typically between 2°C and 8°C (36°F to 46°F). Do not freeze and do not shake the vial, as mechanical stress can denature the protein. The vial should be kept in its original carton to protect it from light until the time of use. Once diluted in normal saline for infusion, the solution should be used immediately or stored under refrigeration for no more than 24 hours. Store the medication in a secure, professional medical refrigerator strictly out of the reach of children.

    Important Note on Ramucirumab 500mg Injection

    The administration of Ramucirumab 500mg Injection is associated with specific vascular and healing risks. Hemorrhage (Bleeding) is a significant risk; severe, sometimes fatal bleeding events (including gastrointestinal hemorrhage) have occurred. It should not be administered to patients with serious bleeding risks.

    Impaired Wound Healing: Because it blocks blood vessel growth, Ramucirumab can disrupt wound healing. It must be withheld for at least 28 days prior to elective surgery and should not be resumed for at least 2 weeks following major surgery until the wound is fully healed.

    Hypertension (high blood pressure) is a common side effect; blood pressure should be monitored before each administration.